Michael Amoroso
President, CEO & DirectorMr. Michael Amoroso serves as Director, President and Chief Executive Officer of Precision BioSciences, Inc. since October 15, 2021. He served as Director at Abeona Therapeutics Inc. since March 19, 2021 until June 11, 2026 and was its Chairman since October 15, 2021 until June 11, 2026. He served as President at Abeona Therapeutics Inc. since March 19, 2021 October 15, 2021 and was its Chief Executive Officer since November 01, 2020 October 15, 2021. Mr. Amoroso served as Chief Operating Officer of Abeona Therapeutics Inc. since November 1, 2020 until March 22, 2021 and had been its Principal executive and operating officer since November 1, 2020 until January 2020. He served as Executive Vice President at Abeona Therapeutics Inc. since January 2021 until March 22, 2021. He has served as Senior Vice President and Chief Commercial Officer at Abeona Therapeutics Inc. since July 9, 2020. Prior to joining Abeona, Mr. Amoroso held various senior level commercial positions at leading biopharmaceutical companies, including Kite, Eisai Inc. from 2017 to 2018, Celgene Corporation (now a subsidiary of Bristol-Myers Squibb Company) from 2011 to 2017, began his biopharmaceutical career at Aventis (now Sanofi) from 2001 to 2011. He served as Senior Vice President and Head of Worldwide Commercial for Cell Therapy at Kite Pharma, Inc. since August 2018. At Kite, he was responsible for the company’s worldwide commercial organization leading the commercialization efforts for the autologous CAR T-cell therapy, YESCARTA® and the future cell therapy pipeline. Mr. Amoroso served as Senior Vice President of Americas Commercial - Oncology Business Group at Eisai Inc. from September 25, 2017 to August 2018. Mr. Amoroso has extensive experience in oncology and other therapeutic areas, led Eisai's Americas Oncology Commercial team in creating and driving commercial strategies for the company's approved products, pipeline assets and late-stage compounds approaching the commercialization stage. In addition to his functional responsibilities, he served as a Member of the Eisai Inc. Previously, Mr. Amoroso worked at Celgene for six years in several commercial roles before serving as the organization’s Commercial Lead for CAR T-cell therapy programs. He is tremendously successful in launching oncology brands, developing and collaborating on disease awareness initiatives, repositioning global brand plans, crafting development plans with R&D and medical colleagues and leading large cross-functional teams in working together to deliver high quality value to customers and patients. He joined Eisai from Celgene, where he spent six years in a variety of marketing roles. Most recently, he served as Commercial Head, Global Markets for CAR-T programs, in which he developed the company's global organizational model to commercialize cell therapies involving specialized manufacturing and customer services for lymphoma and myeloma patients. He held prior roles in Global Marketing for the GI Oncology Franchise and in US Oncology Marketing where he specialized in the breast, lung and pancreas cancer segments. Before Celgene, he served in a number of sales, sales leadership and marketing roles over his 10-plus year tenure at Sanofi Aventis, including being the brand lead for an oncology product with eight indications. He received his Executive Master of Business Administration degree in Management from the New York University's Stern School of Business. He earned B.A. in Biological Sciences, summa cum laude, from Rider University.
Positions
- Company NamePrecision BioSciences, Inc.Stock CodeDTILPositionPresident, CEO & DirectorColleagues
- KJKevin J. BuehlerIndependent Chairman
- JAJohn Alexander KellyChief Operating Officer
- DSDario ScimecaChief Legal Officer & Secretary
- JJJefferson J. SmithCo-Founder & Chief Research Officer
- NTNaresh TannaChief Financial Officer
- GJGeno J. GermanoIndependent Director
- SLShari Lisa PireIndependent Director
- MBMelinda BrownIndependent Director
